{"id":3930,"date":"2026-10-27T09:00:00","date_gmt":"2026-10-27T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3930"},"modified":"2026-10-27T20:53:07","modified_gmt":"2026-10-28T00:53:07","slug":"beam-301-shows-early-human-metabolic-correction","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3930","title":{"rendered":"BEAM 301 Shows Early Human Metabolic Correction"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Beam Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Phase I\/II initial clinical data<\/p>\n

Modality<\/strong><\/p>\n

In vivo LNP-delivered base editing<\/p>\n

Asset<\/strong><\/p>\n

BEAM-301<\/p>\n

Target<\/strong><\/p>\n

G6PC1 R83C allele<\/p>\n

Disease Area<\/strong><\/p>\n

Glycogen storage disease type Ia<\/p>\n

Summary<\/h4>\n

Beam reported initial Phase I\/II human data for liver-directed base editing in glycogen storage disease type Ia on 27 October. Two of three patients in the 40 mg cohort reached the protocol\u2019s 15-hour controlled-fasting ceiling and ceased starch supplementation at latest assessment. The six-patient open-label dataset is early and includes serious treatment-related events.<\/p>\n

Six R83C-positive participants received one intravenous LNP dose: three at 20 mg and three at 40 mg. Median follow-up was 7.6 months. Median time to fasting hypoglycemia rose from 2.5 hours at baseline to 15.0 hours at day 36 in the higher-dose cohort; one higher-dose participant had no first-assessment increase. Four of six patients had treatment-related serious adverse events, including three grade-3 infusion reactions; diarrhea and rhabdomyolysis were reported and resolved. There were no reported dose-limiting toxicities or grade-4\/5 treatment-emergent events. A 60 mg cohort is enrolling. These are new data, beyond the 13 October future presentation notice.<\/p>\n

Deep Analysis<\/h4>\n

The result links a one-time genetic intervention to a directly disease-relevant physiology measure: endogenous glucose production during fasting. That is stronger than editing-efficiency data alone. Yet the 15-hour challenge is a capped protocol endpoint, not a durability or cure measure. Individual follow-up, genotype, baseline diet and the unresponsive patient matter. Four related serious events in six patients constrain dose escalation and make infusion management central to a viable product. Liver LNP access is plausible, but the release does not provide tissue editing fraction, allele-specific off-target profiling, long-term liver safety, or durability beyond the current follow-up. The R83C-specific approach narrows the addressable population and demands validated genetic screening and scalable LNP manufacture.<\/p>\n

Company and Product Background<\/h4>\n

GSDIa stems from G6PC1 deficiency and causes dangerous fasting hypoglycemia. BEAM-301 uses a liver-targeted lipid nanoparticle to deliver base-editing reagents designed to correct the R83C allele without a double-strand DNA break.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> in-vivo base editing restored enough hepatic G6PC1 activity to change daily disease management; dose-response and fasting data support it.<\/li>\n
  • Interpretation B:<\/strong> a small uncontrolled cohort and modified supportive care exaggerate durable benefit; short follow-up and one nonresponder support caution.<\/li>\n
  • Upgrade<\/strong> with sustained off-starch euglycemia, detailed metabolic flux, longer safety, editing and genotoxicity analyses. Downgrade<\/strong> with rebound hypoglycemia or recurring serious infusion reactions. Falsification:<\/strong> later cohorts fail to reproduce physiologic improvement at a tolerable dose.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: BEAM-301 is a credible early human proof of mechanism for liver base editing, but neither lifelong correction nor a workable approval path is established.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: mixed (positive physiology, notable safety burden). Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Beam reported initial Phase I\/II human data for liver-directed base editing in glycogen storage disease type Ia on 27 October. Two of three patients in the 40 mg cohort reached the protocol\u2019s 15-hour controlled-fasting…<\/p>\n","protected":false},"author":1,"featured_media":3946,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[269,39,1236,1237,925],"class_list":["post-3930","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-base-editing","tag-beam-therapeutics","tag-beam-301","tag-glycogen-storage-disease","tag-lipid-nanoparticle"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3930"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3930\/revisions"}],"predecessor-version":[{"id":3950,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3930\/revisions\/3950"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3946"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}